Non-invasive methods have been proposed as surrogate markers for liver biopsy. It was shown that serum hyaluronic acid (HA) level increase with the development of liver fibrosis. The present study aims to determine serum HA level cutoff points for predicting liver fibrosis. Serum HA level in chronic hepatitis patients (n=60) are divided into two groups, group1: included 30 patients, there were positive for anti-HCV (antibodies), group2: included 30 patients, there were positive for HBsAg, and controls (n=10) were assessed by ELISA and liver histopathological parameters were evaluated by the modified Knodell score and microscopic examination of liver biopsies. The results showed that individuals in healthy control group have normal levels of HA (mean 14.3, SD: 5.5) while the levels of HA were elevated in patients of HCV alone (mean 103.6±28.0) and in patient of HCV (mean 104.5± 37.5).Also levels of HA were poorly elevated in HBV alone (mean 62.2± 15.5) and in HBV (mean 45.8± 12.4).The comparison between the studied groups regarding to the level of HA showed that a significant difference was observed between healthy group and HBV & HCV groups (P < 0.001).HA levels and stages of fibrosis were well correlated in patients of HBV and HCV group. Where, this is a significant increase in HA levels when considering F0 to F6 scores by liver biopsy (P < 0.001). Serum HA levels are well correlated with HAI In patients Of HBV & HCV groups where, there was significant increase in HA levels by increase of HAI in liver biopsy at P < 0.001.
Fibrosis is a hallmark histologic event of viral hepatitis and is characterized by the excessive accumulation and reorganization of the extracellular matrix (ECM). The gold standard for assessment of fibrosis is liver biopsy. As this procedure has various limitations, including risk of patient injury and sampling error. Serum Hyaluronic acid as non invasive marker for liver fibrosis is desirable. The present study aims to determine the serum hyaluronic acid (HA) levels as biochemical marker of hepatic fibrosis and cirrhosis and correlate it with the degree of hepatic fibrosis. Serum HA level in chronic hepatitis patients (n=60) are divided into two groups, group1: included 30 patients positive for anti-HCV (antibodies), group 2 included 30 patients positive for HBsAg, and controls (n=10) were assessed by ELISA and liver histopathological parameters were evaluated by the modified Knodell score and microscopic examination of liver biopsies from patients. Individuals in healthy control group have normal levels of HA (mean 14.3, SD: 5.5) while the levels of HA were elevated in patients of HCV alone (mean 103.6±28.0) and in patient of HCV (mean 104.5± 37.5).Also levels of HA were poorly elevated in HBV alone (mean 62.2± 15.5) and in HBV (mean 45.8± 12.4). showed that serum HA levels are well correlated with HAI in patients of HBV & HCV groups where, there was significant increase in HA levels by increase of HAI by liver biopsy P < 0.001.HA levels and stages of fibrosis were well correlated in patients of HBV and HCV group. Where, this is a significant increase in HA levels when Considering F0 to F6 scores by liver biopsy (P < 0.001). Serum HA is a useful non-invasive marker of liver fibrosis. There is a strong positive correlation between serum HA levels and degree of liver fibrosis. The concentration of serum HA rises according to progression of liver fibrosis.
Background: Due to the emergence of resistance to available anticancer agents, the demand for new cytotoxic agents has grown. Objective: This study aims at synthesis and cytotoxic evaluation of new acrylic acid derivatives bearing quinolinone and halogenated quinolinone derivatives against three cancer cell lines. Methods: New acrylic acid derivatives bearing quinolinone and halogenated quinolinone moieties were synthesized and screened for their cytotoxic activity against breast MCF-7, liver HepG2, and colon HCT-116 cancer cell lines. Conclusion: Acrylic acid derivatives bearing quinolinone and halogenated quinolinone moieties represent an important core and could be used as a lead for further development of drug compounds in order to achieve promising therapeutic results.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.